This work is licensed under the Creative Commons Attribution 4.0 International License.
Dubrey S, Hawkins P, Falk R. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart 2011; 97(1): 75–84.DubreySHawkinsPFalkRAmyloid diseases of the heart: assessment, diagnosis, and referralHeart2011971758410.1136/hrt.2009.19040521148582Search in Google Scholar
Fine NM, Davis MK, Anderson K, Delgado DH, Giraldeau G, Kitchlu A, Massie R, Narayan J, Swiggum E, Venner CP. Canadian Cardiovascular Society/Canadian Heart Failure Society joint position statement on the evaluation and management of patients with cardiac amyloidosis. Can J Cardiol 2020; 36(3): 322–34.FineNMDavisMKAndersonKDelgadoDHGiraldeauGKitchluAMassieRNarayanJSwiggumEVennerCPCanadian Cardiovascular Society/Canadian Heart Failure Society joint position statement on the evaluation and management of patients with cardiac amyloidosisCan J Cardiol20203633223410.1016/j.cjca.2019.12.03432145862Search in Google Scholar
Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 2005; 95(4): 535–7.MurtaghBHammillSCGertzMAKyleRATajikAJGroganMElectrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvementAm J Cardiol2005954535710.1016/j.amjcard.2004.10.02815695149Search in Google Scholar
Stana A, Matei C, Ginghină C. Factori de prognostic clinici şi paraclinici în amiloidoza cardiacă - Studiu retrospectiv. Romanian Journal of Cardiology 2011; 21(4): 322–4.StanaAMateiCGinghinăCFactori de prognostic clinici şi paraclinici în amiloidoza cardiacă - Studiu retrospectivRomanian Journal of Cardiology20112143224Search in Google Scholar
Phelan D, Collier P, Thavendiranathan P, Popović ZB, Hanna M, Plana JC, Marwick TH, Thomas JD. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 2012; 98(19): 1442–8.PhelanDCollierPThavendiranathanPPopovićZBHannaMPlanaJCMarwickTHThomasJDRelative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosisHeart201298191442810.1136/heartjnl-2012-30235322865865Search in Google Scholar
Baccouche H, Maunz M, Beck T, Gaa E, Banzhaf M, Knayer U, Fogarassy P, Beyer M. Differentiating cardiac amyloidosis and hypertrophic cardiomyopathy by use of three-dimensional speckle tracking echocardiography. Echocardiography 2012; 29(6): 668–77.BaccoucheHMaunzMBeckTGaaEBanzhafMKnayerUFogarassyPBeyerMDifferentiating cardiac amyloidosis and hypertrophic cardiomyopathy by use of three-dimensional speckle tracking echocardiographyEchocardiography20122966687710.1111/j.1540-8175.2012.01680.x22486396Search in Google Scholar
Stricagnoli M, Cameli M, Incampo E, Lunghetti S, Mondillo S. Speckle tracking echocardiography in cardiac amyloidosis. Heart Fail Rev 2019; 24(5): 701–7.StricagnoliMCameliMIncampoELunghettiSMondilloSSpeckle tracking echocardiography in cardiac amyloidosisHeart Fail Rev2019245701710.1007/s10741-019-09796-z30989593Search in Google Scholar
Kristen AV, Perz JB, Schonland SO, Hansen A, Hegenbart U, Sack F-U, Goldschmidt H, Katus HA, Dengler TJ. Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis. J Heart Lung Transplant 2007; 26(12): 1313–9.KristenAVPerzJBSchonlandSOHansenAHegenbartUSackF-UGoldschmidtHKatusHADenglerTJRapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosisJ Heart Lung Transplant200726121313910.1016/j.healun.2007.09.01418096484Search in Google Scholar
Minnema MC, Nasserinejad K, Hazenberg B, Hegenbart U, Vlummens P, Ypma PF, Kröger N, Wu KL, Kersten MJ, Schaafsma MR. Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial. Haematologica 2019; 104(11): 2274.MinnemaMCNasserinejadKHazenbergBHegenbartUVlummensPYpmaPFKrögerNWuKLKerstenMJSchaafsmaMRBortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trialHaematologica201910411227410.3324/haematol.2018.213900682161030923094Search in Google Scholar
Barrett CD, Alexander KM, Zhao H, Haddad F, Cheng P, Liao R, Wheeler MT, Liedtke M, Schrier S, Arai S. Outcomes in patients with cardiac amyloidosis undergoing heart transplantation. JACC Heart Fail 2020; 8(6): 461–8.BarrettCDAlexanderKMZhaoHHaddadFChengPLiaoRWheelerMTLiedtkeMSchrierSAraiSOutcomes in patients with cardiac amyloidosis undergoing heart transplantationJACC Heart Fail202086461810.1016/j.jchf.2019.12.01332387068Search in Google Scholar
Release FN. FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis. 2019. https://www.fda.gov/ (accessed 28.01.2021).ReleaseFNFDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis2019https://www.fda.gov/ (accessed 28.01.2021).Search in Google Scholar
Release PP. European comissioon approves Vyndaqel®, the first treatment in the EU for transthyretin amyloid cardiomyopathy (ATTR-CM). 2020. https://www.pfizer.com/news/ (accessed 28.01. 2021).ReleasePPEuropean comissioon approves Vyndaqel®, the first treatment in the EU for transthyretin amyloid cardiomyopathy (ATTR-CM)2020https://www.pfizer.com/news/ (accessed 28.01. 2021).Search in Google Scholar
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018; 379(11): 1007–16.MaurerMSSchwartzJHGundapaneniBElliottPMMerliniGWaddington-CruzMKristenAVGroganMWittelesRDamyTTafamidis treatment for patients with transthyretin amyloid cardiomyopathyN Engl J Med20183791110071610.1056/NEJMoa180568930145929Search in Google Scholar
release FN. FDA grants accelerated approval to Darzalex Faspro for newly diagnosed light chain amyloidosis. 2021. https://www.fda.gov/ (accessed 28.01.2021).release FNFDA grants accelerated approval to Darzalex Faspro for newly diagnosed light chain amyloidosis2021https://www.fda.gov/ (accessed 28.01.2021).Search in Google Scholar
Sanchorawala V, Sarosiek S, Schulman A, Mistark M, Migre ME, Cruz R, Sloan JM, Brauneis D, Shelton AC. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. Blood 2020; 135(18): 1541–7.SanchorawalaVSarosiekSSchulmanAMistarkMMigreMECruzRSloanJMBrauneisDSheltonACSafety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 studyBlood2020135181541710.1182/blood.2019004436719318531978210Search in Google Scholar
Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Bumma N, Kaufman JL. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood 2020; 136(1): 71–80.PalladiniGKastritisEMaurerMSZonderJMinnemaMCWechalekarADJaccardALeeHCBummaNKaufmanJLDaratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDABlood20201361718010.1182/blood.2019004460733289732244252Search in Google Scholar
Feng D, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW, Syed II, Hughes DA, Lust JA, Jaffe AS. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 2007; 116(21): 2420–6.FengDEdwardsWDOhJKChandrasekaranKGroganMMartinezMWSyedIIHughesDALustJAJaffeASIntracardiac thrombosis and embolism in patients with cardiac amyloidosisCirculation2007116212420610.1161/CIRCULATIONAHA.107.69776317984380Search in Google Scholar
Giancaterino S, Urey MA, Darden D, Hsu JC. Management of arrhythmias in cardiac amyloidosis. JACC Clin Electrophysiol 2020; 6(4): 351–61.GiancaterinoSUreyMADardenDHsuJCManagement of arrhythmias in cardiac amyloidosisJACC Clin Electrophysiol2020643516110.1016/j.jacep.2020.01.00432327068Search in Google Scholar
El-Am EA, Dispenzieri A, Melduni RM, Ammash NM, White RD, Hodge DO, Noseworthy PA, Lin G, Pislaru SV, Egbe AC. Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis. Am J Cardiol 2019; 73(5): 589–97.El-AmEADispenzieriAMelduniRMAmmashNMWhiteRDHodgeDONoseworthyPALinGPislaruSVEgbeACDirect current cardioversion of atrial arrhythmias in adults with cardiac amyloidosisAm J Cardiol20197355899710.1016/j.jacc.2018.10.079637868530732713Search in Google Scholar
Martinez-Naharro A, Gonzalez-Lopez E, Corovic A, Mirelis JG, Baksi AJ, Moon JC, Garcia-Pavia P, Gillmore JD, Hawkins PN, Fontana M. High prevalence of intracardiac thrombi in cardiac amyloidosis. Am J Cardiol 2019; 73(13): 1733–4.Martinez-NaharroAGonzalez-LopezECorovicAMirelisJGBaksiAJMoonJCGarcia-PaviaPGillmoreJDHawkinsPNFontanaMHigh prevalence of intracardiac thrombi in cardiac amyloidosisAm J Cardiol201973131733410.1016/j.jacc.2019.01.03530947929Search in Google Scholar
Cheung CC, Roston TM, Andrade JG, Bennett MT, Davis MK. Arrhythmias in cardiac amyloidosis: challenges in risk stratification and treatment. Can J Cardiol 2020; 36(3): 416–23.CheungCCRostonTMAndradeJGBennettMTDavisMKArrhythmias in cardiac amyloidosis: challenges in risk stratification and treatmentCan J Cardiol20203634162310.1016/j.cjca.2019.11.03932145868Search in Google Scholar
Mitrani LR, De Los Santos J, Helmke S, Biviano AB, Maurer MS. Anticoagulation with warfarin versus novel oral anticoagulants in atrial fibrillation in amyloid transthyretin amyloidosis cardiomyopathy: a retrospective cohort study. J Card Fail 2019; 25(8): S82.MitraniLRDe Los SantosJHelmkeSBivianoABMaurerMSAnticoagulation with warfarin versus novel oral anticoagulants in atrial fibrillation in amyloid transthyretin amyloidosis cardiomyopathy: a retrospective cohort studyJ Card Fail2019258S8210.1016/j.cardfail.2019.07.233Search in Google Scholar
Mohanty S, TRIVEDI CG, Gallinghouse J, Della Rocca DG, Gianni C, MacDonald B, Mayedo A, Bassiouny M, Gallinghouse G, Burkhardt J. Best Anticoagulation Strategy for Stroke Prophylaxis in Atrial Fibrillation Patients With Amyloidosis. Circulation 2020; 142(Suppl_3): A15073-A.MohantySTRIVEDICGGallinghouseJDella RoccaDGGianniCMacDonaldBMayedoABassiounyMGallinghouseGBurkhardtJBest Anticoagulation Strategy for Stroke Prophylaxis in Atrial Fibrillation Patients With AmyloidosisCirculation2020142Suppl_3A15073-A10.1161/circ.142.suppl_3.15073Search in Google Scholar
Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005; 112(13): 2047–60.FalkRHDiagnosis and management of the cardiac amyloidosesCirculation20051121320476010.1161/CIRCULATIONAHA.104.48918716186440Search in Google Scholar
Dispenzieri A, Gertz M, Kyle R, Lacy M, Burritt M, Therneau T, Greipp P, Witzig T, Lust J, Rajkumar S, Fonseca R, Zeldenrust S, McGregor C, Jaffe A. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 15(22): 3751–7.DispenzieriAGertzMKyleRLacyMBurrittMTherneauTGreippPWitzigTLustJRajkumarSFonsecaRZeldenrustSMcGregorCJaffeASerum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosisJ Clin Oncol200415223751710.1201/9781420037494-24Search in Google Scholar
Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30(9): 989.KumarSDispenzieriALacyMQHaymanSRBuadiFKColbyCLaumannKZeldenrustSRLeungNDingliDRevised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurementsJ Clin Oncol201230998910.1200/JCO.2011.38.5724367568022331953Search in Google Scholar
Lilleness B, Ruberg FL, Mussinelli R, Doros G, Sanchorawala V. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood 2019; 133(3): 215–23.LillenessBRubergFLMussinelliRDorosGSanchorawalaVDevelopment and validation of a survival staging system incorporating BNP in patients with light chain amyloidosisBlood201913332152310.1182/blood-2018-06-85895130333122Search in Google Scholar
Pun SC, Landau HJ, Riedel ER, Jordan J, Anthony FY, Hassoun H, Chen CL, Steingart RM, Liu JE. Prognostic and added value of two-dimensional global longitudinal strain for prediction of survival in patients with light chain amyloidosis undergoing autologous hematopoietic cell transplantation. J Am Soc Echocardiogr 2018; 31(1): 64–70.PunSCLandauHJRiedelERJordanJAnthonyFYHassounHChenCLSteingartRMLiuJEPrognostic and added value of two-dimensional global longitudinal strain for prediction of survival in patients with light chain amyloidosis undergoing autologous hematopoietic cell transplantationJ Am Soc Echocardiogr2018311647010.1016/j.echo.2017.08.017598566429111123Search in Google Scholar
Adam R, Jercan A, Badelita S, Coriu D, Stan C, Serban M, Beladan C, Rosca M, Balahura A, Ginghina C. P216 Cardiac amyloidosis is not a single disease: an echocardiographic study of light chain vs transthyretin forms. Eur Heart J Cardiovasc Imaging 2020; 21(Supplement_1): jez319. 083.AdamRJercanABadelitaSCoriuDStanCSerbanMBeladanCRoscaMBalahuraAGinghinaCP216 Cardiac amyloidosis is not a single disease: an echocardiographic study of light chain vs transthyretin formsEur Heart J Cardiovasc Imaging202021Supplement_1jez319. 08310.1093/ehjci/jez319.083Search in Google Scholar
Suhr OB, Anan I, Backman C, Karlsson A, Lindqvist P, Mörner S, Waldenström A. Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis? J Intern Med 2008; 263(3): 294–301.SuhrOBAnanIBackmanCKarlssonALindqvistPMörnerSWaldenströmADo troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis?J Intern Med2008263329430110.1111/j.1365-2796.2007.01888.x18069997Search in Google Scholar
Kristen AV, Maurer MS, Rapezzi C, Mundayat R, Suhr OB, Damy T, investigators T. Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis–Report from the Transthyretin Amyloidosis Outcome Survey (THAOS). PLoS One 2017; 12(4): e0173086.KristenAVMaurerMSRapezziCMundayatRSuhrOBDamyTinvestigators TImpact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis–Report from the Transthyretin Amyloidosis Outcome Survey (THAOS)PLoS One2017124e017308610.1371/journal.pone.0173086538303028384285Search in Google Scholar